Credit: Google News
OSLO, Norway–(BUSINESS WIRE)–OncoImmunity has become the first company to obtain a CE-IVD mark for
the clinical use of a machine-learning based neoantigen prediction
technology. This quality assurance certification represents an important
step in raising the standards for the use of neoantigen prediction
technologies for the design of personalized cancer vaccines and cell
therapies.
The certification means that personalized cancer vaccine and cell
therapy companies can now meet their own quality assurance requirements
for their clinical development by leveraging OncoImmunity’s proven
quality assurance methodology. OncoImmunity’s neoantigen prediction
technology, known as the Immuneoprofiler™, allows cancer
immunotherapy companies to gain access to a quality assured prediction
technology that also has superior performance in predicting the
presentation of neoantigens to the tumor cell surface.
Richard Stratford CEO at OncoImmunity said:
“At OncoImmunity we understand intimately the complexity of neoantigen
prediction and the need to select neoantigens for personalized cancer
immunotherapy to a high clinical standard. We have designed
machine-learning solutions to fill some of the gaps in the neoantigen
prediction challenge and this certification of the Immuneoprofiler™
will facilitate both cost-saving and time-efficient filing for the
accreditation of our partners cancer immunotherapy platforms”
About CE-IVD
The CE-mark (CE-IVD) indicates that an IVD device complies with the
European In Vitro Diagnostics Directive (98/79/EC), and that the device
may be legally commercialized and distributed in the EU.
About OncoImmunity
OncoImmunity is a machine-learning company offering a proprietary
technology to address the key knowledge gaps in the prediction of bona
fide immunogenic neoantigens for personalized cancer
immunotherapy. OncoImmunity’s software facilitates effective patient
selection for cancer immunotherapy and identifies neoantigen targets for
truly personalized cancer vaccines & cell therapies in a clinically
actionable time-frame.
Credit: Google News
